CBFB and nonpapillary renal cell carcinoma: Therefore, although there has been relatively poor agreement between prior VHL-associated synthetic lethality datasets to date24–31,34, there is now compelling evidence that CBF-β, along with RUNX proteins, is an emerging therapeutic target for ccRCC.